Ahmet Emin ERBAYCU, Serpil TEKGÜL, Günseli BALCI, Nuran KATGI, Emine KARARMAZ, Arzu Güler İZMİR, Pala Emel ÖZDEN, Dilek KALENCİ, Salih Zeki GÜÇLÜ

Akciğer kanserinde serum CA-125 düzeyi ölçümünün hastalığa ait özellikler ve tedaviye yanıt ile ilişkisi

Akciğer kanserli hastalarda tümör markerları tanıdan çok, tümörün vücutta yaygınlığının ve prognozun tayini ile tedavinin takibinde kullanılır.Çalışmaya Şubat 2007 ve Haziran 2009 tarihleri arasında histopatolojik olarak tanı alan 105 akciğer kanserli hasta ve 39 sağlıklı birey "kontrol grubu" olarak alındı. Serum CA-125 düzeyi, akciğer kanserli hastaların tanıları anında, kemoterapi alan hastalarda 3. küre geldiklerinde ve tedavi bitiminde, radyoterapi (RT) alan veya opere olan hastalardan tedavilerinin bitiminden ortalama 1- 3 ay sonra ölçüldü.Akciğer kanserli hastalarda tanı anında serum CA-125 101.9 U/ml sağlıklı kontrol grubunda 8.5 U/ml idi (p=0,000). Tedavi sonrası progresyon gösteren hastalarda serum CA-125 düzeyi anlamlı şekilde yüksek bulundu (p=0.03). Akciğer kanserli hastalarda ilk yanıt değerlendirmede ve tedavi sonrası ölçülen serum CA-125 düzeyleri tümör hücre tipi, tümör hücre alt tipi ve hastalığın evresine göre farklılık göstermedi.Serum CA-125 düzeyi akciğer kanserli hastalarda sağlıklı kişilere göre belirgin şekilde yüksektir. Akciğer kanserinin yaygınlığı ve tümör histopatolojisi ile ilişki göstermemektedir. Tedavi sonrası ölçülen yüksek düzeyler tedaviye yanıtsızlık ile ilişkilidir.

The relation of serum CA-125 level measurement with disease characteristics and response to treatment

Tumor markers are used in the following-up of the treatment, determination of the prognosis and the tumor's extensive in the body more than diagnosis of the tumor in the patients with the lung cancer.The patients diagnosed lung cancer between February 2007 and June 2009 were included into the study. 105 patients with lung cancer and 39 healthy individuals as "control group" were included. Serum CA-125 levels of the patients with lung cancer were measured in the determination of diagnosis, during the 3rd cure of chemotherapy and at the end of the treatment in the patients performed chemotherapy; and the CA-125 levels were measured approximately 1-3 months after the treatment in patients performed RT or had operation.CA-125 levels in the patients with lung cancer were 101.9 U/ml during the process following the determination of diagnosis and were 8.5 U/ml (p=0.000) in healthy control group. In patients progressing after the treatment, serum CA-125 levels were found significantly high (p=0.03). In the the evaluation of first response and after treatment in patients with lung cancer, serum CA-125 levels did not vary according to tumor cell type, tumor cell subtype and the stage of the disease.Serum CA-125 levels in patients with lung cancer is significantly higher compared to healthy individuals. This is not associated with the extensive of tumor and histopathology. High levels measured after the treatment is associated with the resistance to treatment.

PDF

___

1. Butch AW & Pappas AA: Tumor markers. In; Tretz Textbook of Clinical Biochomistry 2. Edition. Eds. Burtis CA & Ashwood ER, Saunders Company, USA, pp; 483-500, 1994.
2. Chon DW & Sell S: Tümör markers. Ün: Tietz Textbook of Clinical Brochemistry. 2. Edition. Eds: Burtis CA & Ashwood ER. Saunders Company, USA, pp: 483-500, 1994.
3. Berthiot G, Marechal F, Cattan A, Deltour G. Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung. Biomed Pharmacother 1989; 43: 613-20.
4. Kimura Y, Hamamoto N, Miyagawa N, Kataoka M, Lio A. Serum CA-125 level is a good prognostic Indicator in lung cancer. Br J Cancer 1990; 62: 676-8.
5. Diez M, Cerdan F, Ortega MD, Torres A, Picardo A, Balibrea JL.. Evaluation of serum CA-125 as a tumor marker in non-small cell lung cancer. Cancer 1991; 67: 150-4.
6. Lou C, DÕ emico T, Harpole D. Clinical and Molecular Prognostic factors and models for non-small cell lung cancer, Pass H, Mitchell J, Johnson D, Turrisi A, Minna J. Lung Cancer: Lippincott Williams and Willcihs 2000; 33: 602-11.